Literature DB >> 21933219

Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer.

J R A Skipworth1, S W M Olde Damink, C Imber, J Bridgewater, S P Pereira, M Malagó.   

Abstract

BACKGROUND: The majority of patients with cholangiocarcinoma present with advanced, irresectable tumours associated with poor prognosis. The incidence and mortality rates associated with cholangiocarcinoma continue to rise, mandating the development of novel strategies for early detection, improved resection and treatment of residual lesions. AIM: To review the current evidence base for surgical, adjuvant and neo-adjuvant techniques in the management of cholangiocarcinoma.
METHODS: A search strategy incorporating PubMed/Medline search engines and utilising the key words biliary tract carcinoma; cholangiocarcinoma; management; surgery; chemotherapy; radiotherapy; photodynamic therapy; and radiofrequency ablation, in various combinations, was employed.
RESULTS: Data on neo-adjuvant and adjuvant techniques remain limited, and much of the literature concerns palliation of inoperable disease. The only opportunity for long-term survival remains surgical resection with negative pathological margins or liver transplantation, both of which remain possible in only a minority of selected patients. Neo-adjuvant and adjuvant techniques currently provide only limited success in improving survival.
CONCLUSIONS: The development of novel strategies and treatment techniques is crucial. However, the shortage of randomised controlled trials is compounded by the low feasibility of conducting adequately powered trials in liver surgery, due to the large sample sizes that are required.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21933219      PMCID: PMC3235953          DOI: 10.1111/j.1365-2036.2011.04851.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  102 in total

1.  Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection.

Authors:  Helmut Witzigmann; Frieder Berr; Ulrike Ringel; Karel Caca; Dirk Uhlmann; Konrad Schoppmeyer; Andrea Tannapfel; Christian Wittekind; Joachim Mossner; Johann Hauss; Marcus Wiedmann
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

2.  Surgical management of hilar cholangiocarcinoma: the Nagoya experience.

Authors:  Hideki Nishio; Masato Nagino; Yuji Nimura
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

3.  Portal vein resection for hilar cholangiocarcinoma.

Authors:  Alan W Hemming; Robin D Kim; Kristin L Mekeel; Shiro Fujita; Alan I Reed; David P Foley; Richard J Howard
Journal:  Am Surg       Date:  2006-07       Impact factor: 0.688

4.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

5.  Radiofrequency ablation for incidentally identified primary intrahepatic cholangiocarcinoma.

Authors:  Witold Zgodzinski; N-Joseph Espat
Journal:  World J Gastroenterol       Date:  2005-09-07       Impact factor: 5.742

6.  Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma.

Authors:  John J Kresl; Steven E Schild; George T Henning; Leonard L Gunderson; John Donohue; Henry Pitot; Michael G Haddock; David Nagorney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-01-01       Impact factor: 7.038

7.  Surgical management of 552 carcinomas of the extrahepatic bile ducts (gallbladder and periampullary tumors excluded). Results of the French Surgical Association Survey.

Authors:  R Reding; J L Buard; G Lebeau; B Launois
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

Review 8.  Achievable outcomes in the management of proximal cholangiocarcinoma: an update prepared using "evidence-based practice" techniques.

Authors:  R P M Killeen; S Harte; D Maguire; D E Malone
Journal:  Abdom Imaging       Date:  2008 Jan-Feb

9.  Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma.

Authors:  Hiroyoshi Furukawa; Hiroki Ikuma; Koiku Asakura; Katsuhiko Uesaka
Journal:  J Surg Oncol       Date:  2009-11-01       Impact factor: 3.454

10.  Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival.

Authors:  H A Pitt; A Nakeeb; R A Abrams; J Coleman; S Piantadosi; C J Yeo; K D Lillemore; J L Cameron
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

View more
  34 in total

1.  Upregulated expression of Mina53 in cholangiocarcinoma and its clinical significance.

Authors:  Xiao-Ping Tan; Qing Zhang; Wei-Guo Dong; Xia-Wen Lei; Zi-Rong Yang
Journal:  Oncol Lett       Date:  2012-02-28       Impact factor: 2.967

2.  Liver transplantation for hilar cholangiocarcinoma--a single-centre experience.

Authors:  Silke Schüle; Annelore Altendorf-Hofmann; Frank Uteß; Falk Rauchfuß; Martin Freesmeyer; Thomas Knösel; Yves Dittmar; Utz Settmacher
Journal:  Langenbecks Arch Surg       Date:  2012-10-09       Impact factor: 3.445

3.  Therapeutic Potential of Adjuvant Stereotactic Body Radiotherapy for Gallbladder Cancer.

Authors:  Anand Mahadevan; Nergiz Dagoglu; Jennifer F Tseng; Khalid Khawaja; Amy Evenson
Journal:  Cureus       Date:  2015-08-10

Review 4.  Advances in endoscopic retrograde cholangiopancreatography for the treatment of cholangiocarcinoma.

Authors:  Dushant S Uppal; Andrew Y Wang
Journal:  World J Gastrointest Endosc       Date:  2015-06-25

5.  Haem oxygenase 1 expression is associated with prognosis in cholangiocarcinoma patients and with drug sensitivity in xenografted mice.

Authors:  S Kongpetch; A Puapairoj; C K Ong; L Senggunprai; A Prawan; U Kukongviriyapan; W Chan-On; E Y Siew; N Khuntikeo; B T Teh; V Kukongviriyapan
Journal:  Cell Prolif       Date:  2016-01-04       Impact factor: 6.831

Review 6.  The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.

Authors:  Hwajeong Lee; Jeffrey S Ross
Journal:  Therap Adv Gastroenterol       Date:  2017-03-28       Impact factor: 4.409

7.  Curative resection of hilar cholangiocarcinoma in a 25-year-old woman: report of a case.

Authors:  Sae Murakami; Tetsuo Ajiki; Kimihiko Ueno; Hidehiro Sawa; Shinobu Tsuchida; Izuru Otsubo; Yuko Yoshida; Kenta Shinozaki; Taro Okazaki; Ippei Matsumoto; Takumi Fukumoto; Yonson Ku
Journal:  Surg Today       Date:  2013-04-12       Impact factor: 2.549

8.  Surgical management trends for cholangiocarcinoma in the USA 1998-2009.

Authors:  Jamie E Anderson; Alan W Hemming; David C Chang; Mark A Talamini; Kristin L Mekeel
Journal:  J Gastrointest Surg       Date:  2012-07-31       Impact factor: 3.452

9.  Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications.

Authors:  Werner Dolak; Florian Schreiber; Hubert Schwaighofer; Michael Gschwantler; Wolfgang Plieschnegger; Alexander Ziachehabi; Andreas Mayer; Ludwig Kramer; Andreas Kopecky; Christiane Schrutka-Kölbl; Gernot Wolkersdörfer; Christian Madl; Frieder Berr; Michael Trauner; Andreas Püspök
Journal:  Surg Endosc       Date:  2013-10-03       Impact factor: 4.584

Review 10.  Update on the management of cholangiocarcinoma.

Authors:  J R A Skipworth; M G Keane; S P Pereira
Journal:  Dig Dis       Date:  2014-07-14       Impact factor: 2.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.